Women's health

Musculoskeletal pain among postmenopausal women in Nigeria: Association with overall and central obesity

BACKGROUND

Menopausal women experience musculoskeletal changes such as muscle atrophy, muscle weakness and osteoporosis-symptoms associated with advancing age coupled with depletion of the female sex hormone, estrogen. Estrogen is important in the maintenance of the integrity of the musculoskeletal system and its reduction in the circulation due to menopausal transition results in reduced resting metabolic rate, lowered energy expenditure, increase in fat mass, and central adipose tissue accumulation.

OBJECTIVE

This study investigated the prevalence of musculoskeletal pain (MSP) in postmenopausal women (PMW) in Nigeria. We examined the association of overall and central obesity with complaints of MSP and the screening potential of obesity measures for risk of musculoskeletal problems among PMW in Nigeria.

METHODS

This was a cross-sectional survey of MSP in 310 PMW in Ibadan, Nigeria. MSP was assessed using the Standardized Nordic Musculoskeletal Questionnaire, and overall and central obesity were assessed using body mass index (BMI), waist/height ratio (WHtR), waist circumference, and waist/hip ratio. Data were analysed using descriptive statistics, chi-square test, and logistic regression models with the probability level at p = 0.05.

RESULTS

Participants were of the modal age group (51-60 years). The highest prevalence rates of MSP were in the lower extremity (189; 61.0%) and the back (164; 52.9%). A direct association was observed between the categories of BMI and lower extremity symptoms (p < 0.05), and the categories of WHtR and waist circumference were associated with back and lower extremity symptoms (p < 0.05). Postmenopausal women had greater odds of reporting MSP across various classes of BMI. WHtR revealed the greatest odds for back (odds ratio = 1.70, 95% confidence interval 1.07-2.75) and lower extremity symptoms (odds ratio = 2.33, 95% confidence interval 1.44-3.78).

CONCLUSION

Lower extremity and back pain symptoms were the most prevalent. For overall and central obesity directly associated with MSP, WHtR seemed the best obesity screening tool for MSP in postmenopausal women.

The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial

We studied the effect of 1-year transdermal estrogen replacement therapy (ERT) on bone mineral density (BMD) and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus (SLE) patients in a randomized, double-blind, placebo-controlled trial. SLE patients were randomly allocated to treatment (estradiol; 50 microg transdermal 17beta-estradiol; n=15) or placebo ( n=17) group. Both groups received 5 mg continuous oral medroxyprogesterone acetate, 500 mg calcium and 400 IU vitamin D(3). L(1)-L(4) spine (LS), left femur and total hip BMD were measured at baseline and at 6 and 12 months. Serum osteocalcin (OC) and degradation products of C-terminal telopeptides of type-I collagen (CTx) levels were measured at baseline and 3, 6, 9, and 12 months. There was a significant difference in the percentage change of LS BMD at 6 months between the two groups (103.24+/-3.74% (estradiol group) vs 98.99+/-3.11% (placebo group); P<0.005). There was a significant decrease within the estradiol group in the CTx levels between baseline and all subsequent visits ( P<0.05). There was no significant difference in SLE disease activity index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) damage index and corticosteroid dose during the study period. Transdermal estradiol may prevent bone loss in postmenopausal SLE women at the lumbar spine and femur, with no increase in disease activity among postmenopausal SLE women receiving transdermal ERT. The high dropout rate (8/15) leads us to the conclusion that efficacy of HRT in a high-risk group such as SLE women can be attained only in a small number of patients, provided all inclusion/exclusion criteria are strictly adhered to.

Autoimmune rheumatic diseases in women

OBJECTIVE

To review the presenting symptoms, possible complications, treatment options, and reproductive considerations for rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and Sjogren's syndrome.

DATA SOURCES

Articles retrieved from MEDLINE and OVID using the search terms women and female in combination with autoimmune disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and Sjogren's syndrome. References identified from citations in these articles were also reviewed.

DATA SYNTHESIS

Autoimmune rheumatic diseases are more common in women than in men and are most likely to manifest during the reproductive years. The reasons for this incidence pattern remain unclear but appear to be related to sex hormones and microchimerism. These diseases have varied clinical presentations that may be local or systemic and range from mild to severe. There is no cure for these autoimmune rheumatic diseases; treatments focus on managing symptoms. Many of the agents used for treating these diseases are contraindicated in pregnancy, posing special considerations for women who develop these diseases during their childbearing years.

CONCLUSION

Knowledge of the presenting symptoms of, treatment options for, and reproductive considerations with these diseases is important for pharmacists who counsel women with them.

Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy

The role of exogenous estrogen in the initiation and maintenance of human SLE remains very controversial. Although cohort studies suggest an increase in the incidence of SLE with both oral contraceptives and hormone replacement therapy, recent retrospective studies suggest that the risk of flare is not increased with hormone replacement therapy. However, exogenous estrogen does increase hypercoagulability, an issue in SLE patients with antiphospholipid antibodies. The prospective SELENA study will ultimately address whether exogenous estrogen increases severe flares in SLE.